PRPF4

Across TCGA pan-cancer cohorts, PRPF4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRPF4 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PRPF4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PRPF4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, OV, and LIHC are the cancer types where PRPF4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	III,IV	0.165	0.833	<.001	22	view →
OV	OS	Median	II,III,IV	0.250	0.692	.009	18	view →
LIHC	OS	Median	All	0.017	0.784	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.487	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PRPF4–BRCA (OS)

Open the BRCA breakdown →